The FDA’s independent Cardiovascular and Renal Drugs Advisory Committee (CRDAC) voted against approving Roxadustat from FibroGen, which would be a novel treatment of anemia resulting from chronic kidney disease (CKD). Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor. FibroGen’s CEO said in a statement that the company believes scientific evidence warrants approval of…